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ABSTRACT 
 
BACKGROUND Central lines (CL) are often used in the care of preterm newborn infants. 
However, they are associated with a number of possible complications including infections. 
Therefore, benefits must be weighed against risks when considering placement of a CL.  
AIM To provide data on the use of Umbilical artery catheters (UACs), Umbilical vein 
catheters (UVCs) and Peripheral inserted central catheters (PICCs) in preterm newborn 
infants admitted to our Neonatal intensive care unit (NICU).  
METHODS We identified infants with a CL admitted to our NICU at Karolinska University 
Hospital, Danderyd from January 1, 2010 to December 31, 2012. The CLs studied were 
UACs, UVCs and PICCs. Clinical data and complications including Central line – associated 
blood stream infection (CLABSI) were studied retrospectively.  
RESULT A total of 192 CLs, including 76 UACs, 51 UVCs and 65 PICCs were placed in 
104 infants. 6 cases of CLABSI occurred (6,5 per 1000 catheter – days). An independent 
predictor of CLABSI was prolonged duration of CL use. No other potential risk factors 
showed any correlation with the development of CLABSI.   
CONCLUTION Prolonged duration of catheter use is an important predictor of CLABSI in 
preterm newborn infants. Clinicians should be aware of this risk when placing a CL and in 
timing the removal of a CL.  
 
ABBREVIATIONS  
BSI Blood Stream Infection 
BW Birth Weight 
CDC Centers for Disease Control 
CL Central Line 
CLABSI Central Line – Associated Blood Stream Infection 
CoNS Coagulase – Negative Staphylococcus 
CRBSI Catheter – Related Blood Stream Infection 
CRP C – Reactive Protein 
GA Gestational Age 
NICU Neonatal Instensive Care Unit 
PICC Peripherally Inserted Central Catheter 
TPN Total Parenteral Nutrition 
UAC Umbilical Artery Catheter 
UVC Umbilical Vein Catheter 
WBC White Blood Cell Count 
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INTRODUCTION 
 
CLs including UACs, UVCs and PICCs are often used in the care of preterm newborn infants 
to provide arterial and venous access. However, the use of CLs is associated with several 
complications including infection (1, 2). For this reason, the decision to insert a CL should 
always be carefully considered for every patient individually, and the benefits must be 
weighed against the risks. A CL should only be inserted when clearly necessary and should be 
removed when no longer essential (3). 
 
INFECTION Newborn and especially preterm infants are naturally more vulnerable to 
infections. When inserting and using CLs it is important to minimize the risk of infection. 
Therefore, an aseptic technique is required when inserting and using intravascular catheters 
(3, 4). 
The most commonly reported pathogens which cause CLABSI are Coagulase – negative 
staphylococci (CoNS) (1, 2, 5 - 9), followed by Staphylococcus Aureus, Enterococci and 
Candida (4, 3). The CL can be contaminated through organisms on the skin which migrate 
from the site of insertion along the surface of the catheter to the catheter tip, direct 
contamination of the catheter through contact with hands or devices, through an infection at 
another site that reaches the CL hematogenously, and by infusion of contaminated fluids (3). 
Also, the characteristics of the material from which the CL is made contribute to the 
vulnerability to microbial colonization and subsequent CLABSI. The same is true of virulence 
factors of the pathogen and host factors in the infant (3).  
  
INSERTION AND MAINTENANCE The umbilical vessels are preferred for intravenous 
and intraarterial access during the first days after birth. The umbilical vein is available for 
catheterization up to seven days after birth, while the umbilical arteries will usually not be 
accessible for more than a couple of days (10). However, by using the alternative technique of 
lateral cut – down, this period may possibly be extended. 
Aseptic conditions during catheter insertion and management are vital for prevention of 
infectious complications (3, 10, 11). It has been shown that the incidence of CLABSI can be 
reduced by education and training for care providers who insert and maintain catheters (3, 11, 
12). In an effort to develop best practices and reduce the rate of complications, a PICC – team 
was formed in our NICU consisting of specialized nurses who provide PICC care.  
Insertion In our NICU the insertion procedures for UACs, UVCs and PICCs are quite 
similar. They are bedside procedures. The skin is cleansed with chlorhexidine solution (0,5 
mg/ml for infants with a birth weight (BW) < 1200 grams and at an age < 1 week, and 5 
mg/ml for infants with a BW > 1200 grams or at an age > 1 week), and sterile drapes are 
placed prior to insertion. ECG or pulse oximetry monitoring is used during the procedure. 
When the catheter is in place, it is flushed with 0.9% NaCl and a continuous infusion is 
started. The catheter position is confirmed by X – ray (10). Umbilical catheterization is 
performed by a physican in sterile gown and gloves and with a nurse assisting, while PICC 
insertion is most commonly performed by a specialized PICC nurse.  
Maintenance The catheter should be manipulated as little as possible. The site of insertion is 
inspected several times a day. Daily review of the catheter is essential to ensure removal at 
the earliest time feasible. Because of the risk for bleeding, the infant is observed for at least 4 
hours after umbilical catheter removal (10). In our NICU, UVCs and UACs are removed at 
the age of 7 days, exceptionally they are used up to ten days. However, when central vascular 
access is needed beyond 7 days, a umbilical catheter is often replaced by a PICC (10).  
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UAC The umbilical artery catheter can be placed either in a high or a low position.  -­‐ High: On X – ray the catheter tip is projected at the level of vertebrae T6 – 10 (4, 10, 
13). -­‐ Low: On X – ray the catheter tip is projected at the level of vertebrae L4 – 5 (4, 10, 
13). 
The catheter position is always checked on X – ray (4, 10).  A catheter tip position between 
vertebrae T11 and L2 should be avoided, as the blood vessels to the abdomen and kidneys 
originate in this area and their blood supply should not be impeded (4). 
Anatomy The umbilical arteries connect to the internal iliac arteries. Therefore a catheter 
introduced into the umbilical artery usually passes from the internal iliac artery into the aorta.  
Indications Frequent blood sampling, measurement of pH and arterial blood gases, 
continuous monitoring of arterial blood pressure and infusion therapy (Vaminolac) (4, 10, 
14). 
The UAC is not used for infusion of drugs used for resuscitation. Blood products, vasoactive 
medications and calcium should not be given through a UAC (10). Hyperosmolar glucose 
should never be given through a UAC because of the risk for potent insulin release and 
hypoglycemia (10). 
Complications Catheter dislocation, hemorrhage, perforation, extravasation, occlusion, 
arterial vasospasm, thromboembolism, renal artery thrombosis, infections (local or systemic) 
(10, 14). 
 
UVC The optimal position for the catheter tip is in the inferior vena cava (1, 10). Intrahepatic 
and portal vein positions should prompt catheter removal. When used for continuous 
infusions, the catheter position is always confirmed by X – ray (10).  
Anatomy The umbilical vein goes from the umbilicus and to the right where it gives off 
several large intrahepatic branches that are distributed directly to the liver tissue. It joins the 
left branch of the portal vein and continues into the ductus venosus, which terminates in the 
inferior vena cava (13).  
Indications Exchange and dilution transfusions, intravenous drug therapy, infusion therapy, 
infusion of vessel – irritating and potentially tissue – damaging substances, blood sampling, 
nutrition (intravenous hyperalimenation), central venous pressure monitoring and achieving 
venous access when the options are limited (1, 10). 
All types of infusions and medications can be given through the UVC (10), assuming that the 
tip is correctly positioned. The UVC is not used for infusion of drugs used for resuscitation 
(10). 
Complications Catheter dislocation, hemorrhage, perforation, extravasation, occlusion, 
broken catheter, embolization, air embolization, thrombosis (including the portal vein), liver 
damage, infections (local or systemic), thrombophlebitis, myocardial rupture, cardiac 
tamponade, arrhythmias, portal hypertension and pleural effusion	   (1, 4, 10). Infusion of 
hyperosmolar solutions in the liver may lead to development of liver damage and portal vein 
thrombosis (10). 
 
PICC PICCs offer an alternative to surgically placed Central venous catheters. It avoids the 
need for sedation and surgical insertion in the operating room (11). (Figure 1 shows a PICC 
placed in the left arm).  
The ideal position for the tip of the PICC is in the inferior or superior vena cava (1, 11, 15). 
The position is always confirmed by X – ray (Figure 2). 
There are two types of PICCs, made of silicone and polyurethane respectively. 
Anatomy The peripheral veins of first choice are the veins of the antecubital fossa, the basilic 
and cephalic veins, as well as the axillary veins. Other vessels used are the femoral and 
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saphenous veins of the leg, the external jugular vein of the neck and the temporal vein of the 
scalp (4). 
Indications Drug administration, parenteral nutrition, fluid therapy, infusions, and 
hemodynamic monitoring (6, 10, 11), although given the small bore of the catheters used, the 
latter is usually not possible in the smaller infants.  
Almost all types of infusions and medications can be administered through a PICC (10), but 
drug incompatibility is often a limitation. Drug incompatibility is a frequent cause of line 
occlusion (16). Given the risk of occlusion, blood products should only be given 
exceptionally (10). Venous blood sampling is not taken through a PICC given the risk of 
occlusion and thrombosis. Injections and temporary infusions should be avoided given the 
risk of infection.  
Complications Catheter dislocation, hemorrhage, perforation, extravasation, occlusion, 
breakage and leakage of the catheter, formation of venous thrombi, embolization, infections 
(local or systemic), thrombophlebitis, arrhythmias, myocardial lesion including perforation, 
pneumothorax, hydrothorax, and pleural effusion (1, 5, 10 - 12). 
 
AIM 
 
To provide data on the use of UACs, UVCs and PICCs in preterm newborn infants admitted 
to our unit. Several aspects were considered, presented in the table below.  
 
CL use 
Duration of CL use 
Cause of CL removal 
Incidence of CL – associated mechanical complications -­‐ Dislodgement -­‐ Reduced peripheral circulation -­‐ Hemorrhage -­‐ Thrombophlebitis -­‐ Occlusion -­‐ Inaproppriate placement of the tip requiring catheter removal -­‐ Extravasation -­‐ Perforation 
Incidence of CL – associated infectious complications -­‐ CLABSI -­‐ Clinical sepsis -­‐ Contamination 
Causative pathogen of infection 
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METHODS 
 
SETTING AND DESIGN This was a retrospective study which covered the period from 
January 1, 2010 to December 31, 2012 in the Neonatal Intensive Care Unit at Karolinska 
University Hospital, Danderyd, Stockholm.  
Infants who fulfilled the following criteria were included: -­‐ Infants born during the above mentioned period.  -­‐ CL placed or in place in our NICU. -­‐ Gestational age week 326 or less. 
We were able to track hospitalizations which preceded as well as followed the stay in our 
NICU. The infants were included if the CL was present at any time during the infant´s stay in 
our NICU. Infants whose CLs were removed before arrival at or inserted after transfer from 
our NICU were excluded. Also, surgery prior to CL introduction or surgery while a CL was in 
place resulted in exclusion of the case. For infants with multiple CLs all CLs were taken into 
account.  
 
DEFINITIONS A CL was defined as an intravascular catheter that terminated in one of the 
great vessels and close to, or inside the heart. We defined CLABSI as a primary BSI (sepsis) 
associated to the usage of a central line. The time of CLABSI onset and Clinical sepsis were 
defined as the first detected sign or symptom, arising ≥ 48 hours after CL introduction or 
within 24 hours after CL discontinuation and not secondary to an infection arising from other 
foci (1, 3, 17). (Tables 1, 2 and 3 show the definitions of infection, including BSI, clinical 
sepsis, and contamination used at our NICU). 
 
CASE ASCERTAINMENT The study population was found through our administrative 
database named PNQn (Perinatal Quality Register neonatal). Dates for PICC insertion and 
removal, as well as indications for PICC insertions were extracted from the PICC – team 
database. Patient characteristics were extracted from medical records found in our electronic 
medical chart (Take Care). The medical records were reviewed to determine whether the 
infants met the inclusion criteria and if the CLABSI criteria were fulfilled. We also reviewed 
the results of each infant´s blood, urine and cerebrospinal fluid tests, as well as X – rays. We 
tracked the status of each infant until at least 48 hours after CL removal. For each infant we 
recorded clinical variables such as gestational age (GA), BW, clinical indication for CL 
placement, type of CL, age of infant at the time of CL placement, duration of catheter use, 
cause of catheter removal, CRP maximum, CL dwell time at the time of CRP maximum, 
antimicrobial therapy, complications (as mentioned in aims), CL dwell time on the day of that 
infection was diagnosed, and hospitalizations at other NICUs.  
 
STATISTICAL ANALYSIS Descriptive characteristics were calculated separately for 
UACs, UVCs and PICCs, as well as for the whole population. All data were expressed as 
numbers and percentages, or as mean, SD, maximum and minimum, and were calculated 
using Microsoft ExcelTM. Data were maintained in Microsoft ExcelTM and were analyzed 
using IBM SPSS Statistic (version 20) and Statistica (version 10). P - values < 0.05 were 
considered statistically significant.  
In order to give all CLs an equal probability for developing CL – associated infections such as 
CLABSI and clinical sepsis, all CLs with a dwell time < 48 hours were excluded (33 CLs) 
when considering these infectious complications. Therefore, statistical analysis considering 
CLABSI and clinical sepsis were performed on a subpopulation consisting of 159 CLs. 
Statistical analysis considering CL contamination were performed on the whole population, as 
contamination can appear at any time during CL use.  
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The incidence of CLABSI and complications were measured as episodes per 1000 catheter – 
days. To identify potential independent risk factors for CLABSI, the Fisher exact test and the 
Mann – Whitney U test were used. As potential risk factors the following were taken into 
account: UAC (yes/no), UVC (yes/no), PICC (yes/no), GA (weeks, numerical value), BW 
(grams, numerical value), administration of TPN (yes/no), antimicrobial therapy prior to 
CLABSI development (yes/no) and duration of CL use (days).  Differences between UACs, 
UVCs and PICCs as regards time until occurrence of CLABSI were analyzed by using Kaplan 
– Meier survival curves and was subsequently compared with a Generalized Wilcoxon log – 
rank test. Further, Kaplan – Meier estimates were performed to show the duration of catheter 
use until occurrence of CLABSI and a Hazard – curve was constructed to estimate the risk of 
developing CLABSI as a function of duration of catheter use.  
 
RESULTS 
 
During the study period 2754 infants were admitted to our NICU. Of these, 303 (11%) infants 
were born at week 326 or earlier, of whom 109 (36%) had a CL placed. Five infants had 
surgery before the introduction of a CL or at the time of an indwelling CL and were excluded. 
Thus, 104 patients were eligible for our study. The total number of CLs included was 192. 
60/104 (57,7%) infants received more than one CL. 34/104 (32,7%) patients who had CLs 
also had these in place at the time of transfer into or out of our NICU. 
The mean GA among the infants was 29,6 ± 1,8 weeks, with a range from 25,1 to 32,9. The 
mean BW was 1325 ± 351 grams, ranging from 720 to 2406. (Demographic characteristics of 
the study population are shown in Table 4).  
The mean duration of catheter use was 4,9 ± 3,7 days, ranging from 0 to 23. The mean age of 
the infant at the time of catheter insertion was 2,2 ± 4,9 days, ranging from 0 to 38. (See table 
5). 
 
UACs were placed in 76/104 (73,1%) infants, of which 68 were placed in a high position and 
8 in a low position. UVCs were placed in 51/104 (49%) infants. PICCs were placed in 65/104 
(62,5%) infants, including 28/65 (43,1%) introduced in the right arm, 29/65 (44,6%) 
introduced in the left arm, 2/65 (3,1%) introduced in the left leg and 6/65 (9,2%) introduced 
in the right leg.  
 
152/192 (79,2%) CLs were removed electively, as they were no longer needed, while 16/192 
(8,3%) were removed because of inappropriate placement of the tip, 15/192 (7,8%) were 
removed because of mechanical complications, and 4/192 (2,1%) were removed because of 
suspected local or systemic infection. 4/192 (2,1%) of the CLs were dislodged.  
In 17/65 (26%) cases of PICC placements the tip was initially placed in an incorrect position 
requiring correction. Of these, in one case the catheter tip was placed in a small peripheral 
vessel, in another the tip was placed in the internal jugular vein and in fifteen cases the tip 
was placed in the heart.  
 
The most frequently used infusion was Total parenteral nutrition (TPN), which was 
administered in 151/192 (78,6%) of all CLs. (Table 6 shows the infusions administered in 
UACs, UVCs, PICCs and in total). 
 
COMPLICATIONS were calculated based on the whole population, which included 192 
CLs. Of these 192, 41 (21,4%) were associated with a complication. Overall, the rate of CL – 
associated complications was 43,7 instances per 1000 catheter days. 4/192 (2,1%) were 
accidentally dislodged, 3/192 (1,6%) developed reduced peripheral circulation, 1/192 (0,5%) 
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developed hemorrhage, 2/192 (1,0%) developed thrombophlebitis, 12/192 (6,3%) were 
occluded, 16/192 (8,3%) had an inappropriate placement of the tip and 3/192 (1,6%) were 
contaminated. Extravasation or perforation did not occur in any of our patients.  
Among the 76 UACs, 17/76 (22,4%) were associated with a complication, and the rate of 
UAC – associated complications was 52,1 instances per 1000 catheter days. Among the 51 
UVCs, 17/51 (33,3%) were associated with a complication, and the rate of UVC – associated 
complications was 131,8 instances per 1000 catheter days. Among the 65 PICCs, 7/65 
(10,8%) were associated with a complication, and the rate of PICC – associated complications 
was 14,5 instances per 1000 catheter days. (Table 7 shows the distribution of complications in 
the three catheter groups).  
 
Rates of CLABSI and Clinical sepsis were calculated based on the subpopulation, which 
included 159 CLs (67 UACs, 30 UVCs and 62 PICCs). During the study period we observed 
6/159 (3,8%) instances of CLABSI. The rate of CLABSI was 6,5 instances per 1000 catheter 
days. CLABSI occurred in 3/67 (4,5%) of the UACs, 1/30 (3,3%) of the UVCs and 2/62 
(3,2%) of the PICCs. (See table 8). In the 6 patients with CLABSI the mean GA was 29,5 ± 
1,4 weeks, the mean BW was 1176 ± 149 g, the mean duration of CL use was 8,3 ± 2,2 days, 
100% recieved TPN and 50% received antimicrobial therapy prior to developing CLABSI. 
(Table 9 summarizes the characteristics of the infants with and without CLABSI). 
 
In our study the infants appeared to develop CLABSI from UACs more frequently (4,5%) 
than from UVCs (3,3%) and PICCs (3,2%), but this difference was not statistically 
significant.  When evaluating CLABSI in relation to potential risk factors, neither the use of 
UACs (p = 0,699), UVCs (p = 1,0), or PICCs (p = 1,0) showed any statistically significant 
association with the development of CLABSI. Nor was there any statistically significant 
association between CLABSI and GA (p = 0,982), BW (p = 0.614), administration of TPN (p 
= 1,0) or having received antimicrobial therapy prior to developing CLABSI (p = 0,689). 
 
There was no statistically significant difference between the three catheter groups in time to 
development of CLABSI using a Kaplan – Meier survival curve (p = 0,156). (Figure 3). 
The risk for developing CLABSI was analyzed as a function of increasing duration of catheter 
use in a hazard curve. The risk was 0.005 at day 5, 0.08 at day 10 and 0.3 at day 15. This 
apparent relationship failed to reach statistical significance. However, this may be due to the 
small sample size and does not rule out the possibility that the risk of developing CLABSI 
increases with increasing duration of catheter use (Figure 4). 
 
Overall, clinical sepsis occurred in relation to 3/159 (1,9%) CLs, of which 1/67 (1,5%) in a 
UAC, 1/30 (3,3%) in a UVC and 1/62 (1,6%) in a PICC.  
 
The incidence of contamination was calculated on the whole population consisting of 192 
CLs. The overall incidence of CL contamination was 3/192 (1,6%), all UAC related, 
including 3/76 (3,9%) of the UACs in total.  
 
The most common causative pathogens were CoNS and S. Aureus, both causing 3/6 cases of 
the CLABSIs each, and 1/3 cases of contamination each. The remaining 1/3 case of 
contamination was caused by a Group A Streptococcus.  
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DISCUSSION 
 
We report results from a retrospective study of neonates with central lines, UACs, UVCs and 
PICCs. The CLs were used in selected cases, in infants with a low GA and a low BW. 
CLABSI has become a major concern in neonates. A retrospective cohort study performed by 
Odetola et al. (18) at a Pediatric intensive care unit suggested that 90% of nosocomial BSIs 
were related to intravascular catheter devices.  
Our main finding was a low incidence of CLABSI. We observed 6 cases of CLABSI among 
159 catheters in a high risk population consisting of preterm newborn infants born at 
gestational week 326 or earlier.  
 
It was difficult to compare studies because of the heterogeneity in context and study 
population, as well as the different definitions of CLABSI. 
Some of the studies we compared our study result with used the definition Catheter – Related 
Blood Stream Infection (CRBSI) instead of CLABSI. CRBSI identifies the catheter as the 
source of the BSI more thoroughly, and requires more specific laboratory testing compared to 
CLABSI (3). The CDC´s Guidelines for the Prevention of Intravascular Catheter – Related 
Infections (3) suggests that CLABSI may overestimate the true incidence of CRBSI.  
 
In the present study the incidence of UVC – associated CLABSI was 3,3% and the risk 
expressed as instances per 1000 catheter – days was 8,1. This is lower than the rate of 
CLABSI reported from a NICU in China, where the incidence of UVC – related septicemia 
was 9,5%, with a rate of 13,6 per 1000 catheter – days (8). 
Compared with a study performed by Advani et al. (5) on children and full term infants at a 
Children´s Center at The John Hopkins Hospital, who reported a rate of PICC – associated 
CLABSI of 2,58 instances per 1000 catheter – days, our rate of PICC – associated CLABSI of 
4,1 instances per 1000 catheter – days is high. However, because of differences in 
immunocompetence and underlying conditions, neonates may not be directly comparable with 
older children. The same study also reported that the incidence of PICC – associated CLABSI 
was higher in children of less than one year of age (5). Therefore, this comparison may not be 
reliable.  
A prospective cohort study performed at a NICU by Chien and coworkers (2) reported 7,2 
instances of CL – related BSI per 1000 UVC – days and 13,1 instances of CL – related BSI 
per 1000 PICC – days. The occurrence of UVC – associated CLABSI was slightly higher in 
our NICU, and the occurrence of PICC – associated CLABSI was lower. Chien´s study had a 
much larger study population, 19 507 infants, compared with our study population of only 
104 infants. It is interesting that our study, based on a small population, finds results very 
similar to those in the larger studies, such as the results reported by Chien´s group (2).  
 
In agreement with previous studies (1, 2, 5 - 9), we found that CoNS is a major causative 
pathogen for development of CLABSI. 
 
The main purpose of our study was to determine potential risk factors for development of 
CLABSI. The causes of nosocomial bloodstream infections are multifactorial (9). In addition 
to CL exposure there are many other factors, especially in the NICU environment, that can 
contribute to the development of a BSI. Therefore, it is difficult to pinpoint a true independent 
contribution to the development of CLABSI.  
Several factors have been noted in earlier studies to have a role in the development of 
CLABSI. These include low GA (19), low BW (2, 20), administration of parenteral nutrition 
(3, 5, 11) and prolonged duration of catheter use (3, 5, 6, 12).  
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Stoll et al. (21) suggested an increase in CL – related BSI as GA and BW decreased. These 
factors did not have a significant effect on CLABSI in our study. However, because our study 
population had a limited range of GA and BW, we may not have had sufficient statistical 
power to address this particular question.  
 
Previous studies have demonstrated an association between administration of parenteral 
nutrition and CLABSI (3, 5, 11). A similar relationship was not shown in our study. However, 
this might be explained by the predominant use of TPN in our study population as 143/159 
(90%) received TPN. All the infants who developed CLABSI received TPN, and this might 
indicate an association with CLABSI at first sight. However, as almost all infants who did not 
develop CLABSI also received TPN, lack of statistical power may have prevented us from 
finding the putative association between TPN and development of CLABSI.  
Several studies have evaluated the effect of increased duration of catheter use on the 
incidence of CLABSI. Consistent with previous studies, our study suggests that prolonged 
duration of catheter use might be an important predictor of CLABSI.  However, we did not 
have a sufficient number of CLABSIs for analysis. Thus, any single event could have a large 
impact on the outcome. However, many other studies with a higher power have suggested a 
correlation between increasing duration of catheter use and the rate of CLABSI (3, 5, 6, 12).  
The CDC´s Guidelines for the Prevention of Intravascular Catheter – Related Infections 
recommends a duration of UAC use of less than 5 days and an duration of UVC use of less 
than 14 days to reduce the incidence of CRBSIs (3).  
Butler – O´Hara et al. (12) found an accelerating risk of UVC – related CLABSI after 7 days 
of use and a stable rate of PICC – related CLABSI for a up to 14 days of use. This study also 
reported that replacement of a UVC with a PICC when central venous access remains 
essential after 7 days, may reduce the incidence of CLABSI (12).  
Our data showed that there is an increased risk for developing CLABSI that rises 16 – fold 
from day 5 to day 10. This was not significant but supports data presented in the literature and 
suggests that the risk of CLABSI increases with prolonged duration of CL use. This may 
warrant considering CL removal after 5 to 10 days of catheter use in effort to reduce the 
incidence of CLABSI. However, considering the low risk presented in our study, the need for 
a CL some times might be more important than the concern for development of an infection. 
 
In our study the PICCs remained in situ longer compared with UACs and UVCs. Also, the 
PICCs only contributed 1/3 of the cases of CLABSI. A study performed by Sengupta et al. (6) 
showed an increase in the risk of PICC – associated CLABSI that warranted PICC 
replacement after 35 days of duration. Therefore, our results, suggesting CL removal after 5 
to 10 days of duration may not include PICCs. Hence, additional studies are needed to 
identify a threshold for catheter dwell time with these three catheters individually.  
 
Several limitations should be considered when interpreting our data. First, our study had a 
small sample size (n = 192). The study was conducted over a three year period, but despite 
this we only captured 6 events of CLABSI. Thus, we did not have a sufficient number of 
CLABSIs to achieve valid outcomes. Second, we included infants with multiple catheters and 
with multiple catheters at the same time. Hence, some infants were counted several times and 
the infant´s individual risk for developing CLABSI was not taken into account. Third, we did 
not control for other potentially confounding factors that may contribute to the development 
of CLABSI. These factors can be patient – related such as underlying health state, 
environmental such as hospitalization and intubation, and CL – related such as line material 
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and position. Finally, we did not have a control group. Clearly, it would have been valuable to 
compare the occurrence of BSIs with a population without any CL. 
 
Our study contributes to increased knowledge of the use of CLs in a very selected population 
of preterm infants born at or below week 326 of gestation. Our data confirm that CLABSI is 
mainly caused by CoNS and that the risk of CLABSI onset drastic increases after 5 to 10 days 
of CL use. Further studies on preterm infants are needed to provide better understanding of 
CLABSI to improve clinical practices. 
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APPENDIX 
 
 
 
Figure 1 A PICC placed in the left arm to show the dressing technique which allows 
inspection of the insertion site.  
 
 
 
 
      A                 B  
 
Figure 2 X – ray showing PICCs placed in the right leg (A) and in the right arm (B).  
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Table 1 Definition of infection. 
Blood stream infection (sepsis) a. ≥ 3 clinical symptoms (table 2) 
b. 1 positive blood culture 
c. ≥ 1 positive laboratory finding (table 3) 
Contamination a. 1 positive blood culture  
Clinical sepsis a. ≥ 2 clinical symptoms (table 2) 
b. At least 1 positive laboratory finding (table 3) 
c. No growth on blood culture 
d. Treatment is introduced  
e. No focus of infection is found 
 
  Table 2 Clinical symptoms of BSI (sepsis). 
Breathing Breathing difficulties (grunting, flaring, retracting, 
tachypnea), increasing need for oxygen (desaturations), 
possible need for ventilatory support 
CNS New or increased apnea with or without bradycardia, 
lethargy, irritability, seizures, temperature instability 
Circulation Impaired peripheral circulation, hypotension, bleeding 
tendency 
Gastrointestinal tract Feeding intolerance, retentions, distended abdomen 
 
  Table 3 Laboratory findings of BSI (sepsis). 
WBC ≤ 5 or ≥ 20 × 109/L 
Neutrophils < 1,5 × 109/L 
Platelets ≤ 100 × 109/L 
CRP ≥ 15 or rising 
Blood glucose Elevated 
Blood gas Metabolic acidosis (BE < − 7 mmol/L) 
X-ray New infiltrates 
Cultures Bacterial growth in blood, urine, or cerebrospinal fluid 
Cerebrospinal fluid Leukocytes > 30 × 106/L, or > 1 leukocyte /500 erytrocytes, 
glucose < 1 or  < 1/3 of the blood glucose level 
 
Table 4 Demographic characteristics of the study population (n = 192). 
 UAC UVC PICC Total 
Number 76 (39,6) 51 (26,6) 65 (33,8) 192 
GA, weeks 
Mean ± SD 
Maximum 
Minimum 
 
29,6 ± 1,6 
32,9 
26,6 
 
29,7 ± 1,6 
32,7 
26,9 
 
28,9 ± 1,8 
32,9 
25,1 
 
29,6 ± 1,8 
32,9 
25,1 
BW, grams 
Mean ± SD 
Maximum 
Minimum 
 
1347 ± 348 
2406 
720 
 
1352 ± 330 
2406 
913 
 
1212 ± 320 
2274 
733 
 
1325 ± 351 
2406 
720 
  Data presented as no (%) or mean, SD, maximum and minimum. 
 
Table 5 Duration of CL use and infant age at the time of CL insertion (n = 192) 	   UAC UVC PICC Total 
Duration of CL use, 
days 
Mean ± SD 
Maximum 
Minimum  
 
 
4,3 ± 2,5 
10 
0 
 
 
2,5 ± 2,5 
9 
0 
 
 
7,5 ± 4,1 
23 
0 
 
 
4,9 ± 3,7 
23 
0 
Infant age at CL 
insertion, days 
Mean ± SD 
Maximum 
Minimum  
 
 
0,3 ± 0,9 
5 
0 
 
 
0,1 ± 0,3 
1 
0 
 
 
6,2 ± 6,8 
38 
0 
 
 
2,2 ± 4,9 
38 
0 
Data presented as mean, SD, maximum and minimum. 
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Table 6 Infusions administered in UAC, UVC, PICC and in total (n = 192). 
 UAC UVC PICC Total 
TPN 61 (80,3) 29 (56,9) 61 (93,8) 151 (78,6) 
Antibiotics (Vancomycin, 
Aminoglycoside, Benzyl penicillin) 
9 (11,8) 15 (29,4) 15 (23,1) 39 (20) 
Erythrocytes 2 (2,6) 4 (7,8) 0  6 (3,1) 
Plasma 7 (9,2) 3 (5,9) 1 (1,5) 11 (5,7) 
Glucose (with heparin 20 U/ 100 ml) 33 (43,4) 24 (47,1) 44 (67,7) 101 (52,6) 
NaCl (with heparin 20 U/ 100 ml) 34 (44,7) 5 (9,8) 3 (4,6) 42 (21,9) 
Calcium 3 (3,9) 3 (5,9) 0 6 (3,1) 
Bicarbonate 2 (2,6) 1 (2,0) 0 3 (1,6) 
Isotonic amino acid solution 7 (9,2) 0 2 (3,1) 9 (4,7) 
Succinyl choline 0 1 (2,0) 0 1 (0,52) 
Thiopental 0 1 (2,0) 0 1 (0,52) 
Caffeine citrate 0 0 2 (3,1) 2 (1,0) 
Data presented as number (%). 
 
Table 7 Catheter – associated complications (n = 192). 
Data are presented as number (%) or events per 1000 catheter – days.  
 
Table 8 CLABSI and Clinically suspected sepsis (n = 159). 	   UAC UVC PICC Total 
CLABSI 3 (4,5) 1 (3,3) 2 (3,2) 6 (3,8) 
CLABSI per 1000 
catheter days 
9,4 8,1 4,1 6,5 
Clinical sepsis 1 (1,5) 1 (3,3) 1 (1,6) 3 (1,9) 
Data presented as number (%) or events per 1000 catheter days. 
 
Table 9 Characteristics of infants with and without CLABSI (n = 159).  
 No 
(%) 
GA 
(weeks) 
BW 
(grams) 
UAC 
(%) 
UVC 
(%) 
PICC 
(%) 
Duration 
of CL use 
(days) 
TPN 
(%) 
Antimicrobial 
therapy prior to 
developing 
CLABSI 
(%) 
CLABSI 6 (3,8) 29,5 ± 
1,4 
1176 ± 
149 
3  
(50) 
1 
(16,7) 
2 
(33,3) 
8,3 ± 2,2 6 
(100) 
3  
(50) 
No 
CLABSI 
153 
(96,2) 
29,3 ± 
1,7 
1282 ± 
330 
64 
(40,3) 
30 
(18,9) 
62 
(37,7) 
5,7 ± 3,3 133 
(83,6) 
92  
(57,9) 
Data presented as no (%) or mean and SD.
 UAC UVC PICC Total 
Total  17 (22,4) 17 (33,3) 7 (10,8) 41 (21,4) 
Complications per 1000 
catheter days 
55,2 
 
131,8 14,5 43,7 
Dislodgement 0 3 (5,9) 1 (1,5) 4 (2,1) 
Reduced peripheral 
circulation 
3 (3,9) 0 0 3 (1,6) 
Hemorrhage 1 (1,3) 0 0 1 (0,5) 
Thrombophlebitis  1 (1,3) 0 1 (1,5) 2 (1,0) 
Catheter occlusion 7 (9,2) 1 (2,0) 4 (6,2) 12 (6,3) 
Inappropriate placement  
of the tip  
2 (2,6) 13 (25,5) 1 (1,5) 16 (8,3) 
Extravasation 0 0 0 0 
Perforation 0 0 0 0 
Contamination 3 (3,9) 0 0 3 (1,6) 
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Figure 3 Time until CLABSI in the three catheter groups UACs, UVCs and PICCs. 
 
 
 
 
Figure 4 The risk of developing CLABSI as a function of the duration of catheter use.  
